Dianthus Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 21, 2026, details the results of the Annual Meeting of Stockholders held by Dianthus Therapeutics, Inc. on that date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol DNTH.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
The following proposals were voted upon by stockholders:
- Proposal 1 (Election of Class II Directors): Stockholders elected Sujay Kango, Anne McGeorge, and Jonathan Violin, Ph.D. to serve until the 2029 annual meeting.
- Sujay Kango: 42,739,315 For; 479,199 Withheld.
- Anne McGeorge: 34,814,377 For; 8,404,137 Withheld.
- Jonathan Violin, Ph.D.: 42,799,946 For; 418,568 Withheld.
- Proposal 2 (Advisory Vote on Executive Compensation): Stockholders approved the compensation of named executive officers.
- For: 41,004,507
- Against: 1,713,043
- Abstain: 500,964
- Proposal 3 (Ratification of Auditors): Stockholders ratified the appointment of Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 46,298,319
- Against: 5,279
- Abstain: 500,471
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the final voting tallies for the Annual Meeting.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Sujay Kango, Anne McGeorge, Jonathan Violin) extending to 2029.
- Note the significant number of votes withheld for director Anne McGeorge (8,404,137) compared to the other nominees.
- Confirm the ratification of Deloitte & Touche, LLP as the auditor for the fiscal year ending December 31, 2026.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 9, 2026) for detailed context on the proposals and executive compensation.